Exendin-4 Fc fusion

JY09 is an exendin-4 Fc fusion protein - a long-acting GLP-1 receptor agonist being developed by Beijing Dongfang Biotech for type 2 diabetes. It's in two Phase 3 trials in China, one against placebo and one head-to-head with dulaglutide, both using HbA1c as the primary endpoint [1][2]. The GLP-1 receptor agonist mechanism is among the most validated in all of metabolic medicine, so the scientific risk here is low; the real question is whether a Chinese biotech can carve out share in a market increasingly dominated by semaglutide and tirzepatide.

JY09 is a novel compound that has not been approved anywhere. Beijing Dongfang Biotech has completed two Phase 1 studies - a first-in-human safety and pharmacokinetics trial (n=41) [3] and a drug-drug interaction study in overweight subjects (n=28) [4] - and has advanced into two concurrent Phase 3 trials. NCT06257966 is an active-comparator trial versus dulaglutide (n=600), and NCT06254014 is a placebo-controlled trial (n=270) [1][2]. Both are listed as active but no longer recruiting, which means enrollment is complete and patients are in the treatment phase. No FDA designations have been reported; this program appears to be running entirely through China's NMPA regulatory pathway. There are no public disclosures about breakthrough or fast-track designations from any regulatory authority. Given that T2DM HbA1c trials typically run 24 to 52 weeks in treatment duration, and both trials closed enrollment by mid-to-late 2024, topline results could plausibly emerge in 2026. However, Beijing Dongfang Biotech has not publicly committed to a readout date.

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. It tells your pancreas to produce more insulin, tells your liver to ease up on dumping glucose into the blood, and tells your brain you're full. In type 2 diabetes, this signaling system is blunted - the body still makes GLP-1, but not enough to keep blood sugar in check [5]. GLP-1 receptor agonists are synthetic versions of this hormone, given as injections, that activate the same receptor at much higher and more sustained levels than the body can achieve on its own. Exendin-4 specifically is a peptide originally found in the saliva of the Gila monster lizard. It binds the GLP-1 receptor and activates it, but unlike human GLP-1, which gets chopped up by an enzyme called DPP-4 within minutes, exendin-4 resists that degradation. Exenatide (branded as Byetta and Bydureon) was the first GLP-1RA approved, based directly on this peptide. JY09 takes exendin-4 and fuses it to an Fc fragment - the tail portion of an antibody that the body recycles rather than clearing, extending the drug's half-life substantially. This is the same engineering trick used in dulaglutide (Trulicity), which fuses a GLP-1 analog to an Fc domain for once-weekly dosing [6]. The GLP-1 receptor is one of the best-validated drug targets in the world: semaglutide, tirzepatide, dulaglutide, liraglutide, and exenatide all hit it, with proven effects on blood sugar, body weight, and cardiovascular outcomes.

The lead registration trial is NCT06257966: a Phase 3, randomized, active-controlled study comparing two dose levels of JY09 against dulaglutide, all added on top of metformin, in 600 patients with type 2 diabetes [1]. The primary endpoint is change from baseline in HbA1c - the standard glycemic control measure that averages blood sugar over roughly three months. Choosing dulaglutide as the comparator is strategic: it sets a bar that's achievable (dulaglutide typically lowers HbA1c by 1.0-1.5 percentage points from baseline) without forcing a comparison against semaglutide, which would be a tougher benchmark [6]. The second trial, NCT06254014, is a placebo-controlled study in 270 T2DM patients, also measuring HbA1c as the primary endpoint [2]. Running both an active-comparator and a placebo-controlled trial in parallel is textbook regulatory strategy - the placebo trial demonstrates absolute efficacy, while the active-comparator trial shows JY09 can at least match an established drug. One concern: neither trial appears to include semaglutide or tirzepatide as a comparator arm. Regulators may approve based on dulaglutide non-inferiority, but prescribers and payers will want to know how JY09 stacks up against the current market leaders. Both trials are being conducted in China, and enrollment is complete.

The model gives this drug a 34% chance of eventually being approved. That figure starts from the historical approval rate for Phase 3 drugs in this area - about 66% - then adjusts based on ten specific facts about the trial and its sponsor. The estimate is pulled up by the trial's blinding approach, and pulled down by the sponsor's weak approval track record, limited earlier-phase results, and the trial's randomized design. The remaining factors are close to average for this stage and don't shift the number much either way.

JY09 is a competent but unremarkable entry into the most crowded space in metabolic medicine. The science will almost certainly work - GLP-1 receptor agonism is as close to a sure thing as drug development gets. But "works" and "matters" are different questions. In a world where semaglutide generates over $20 billion annually and tirzepatide is on a trajectory to match it, a new exendin-4 Fc fusion from a mid-tier Chinese biotech needs a clear differentiation story, and JY09 doesn't appear to have one yet [7]. No weight loss indication is being pursued (the real growth driver in GLP-1RAs right now), no cardiovascular outcomes trial is registered, and no obvious pharmacological advantage over existing agents has been disclosed. The most likely commercial path is as a domestic Chinese alternative to imported GLP-1RAs, competing on price and local manufacturing advantage. That's a viable business, but it's a regional play, not a global one. Check back when Phase 3 topline results drop - likely sometime in 2026. The data to watch: HbA1c reduction versus dulaglutide (non-inferiority would be the minimum; superiority would be a genuine surprise worth noting) and the weight loss data, which will be a secondary endpoint but will determine whether anyone outside China pays attention. If the weight loss numbers are unremarkable, this stays a China-market footnote.